A YORK developer of medical devices has announced the results of clinical trails into its latest product designed to assist wound healing.

Tissue Regenix Group presented the initial results from the clinical study into the efficacy of its DermaPure product at The Symposium on Advanced Wound Care (SAWC) in Las Vegas on Saturday.

The study, which was conducted by the University Hospital of South Manchester NHS Foundation Trust and involved a series of six-week trials on 50 healthy human patients, found DermaPure increased the growth of new blood vessels to aid wound care.

Acute wounds that Tissue Regenix, based at York Science Park, hopes could be treated successfully with DermaPure include surgical incisions and traumatic injuries such as lacerations, abrasions, avulsions, penetrations, bites or burn injuries.

Currently in the United States, 6.5 million patients are afflicted by chronic wounds. Tissue Regenix is targeting the existing $1.4billion market for wound healing devices and equipment, which is anticipated to reach $1.5 billion by 2016.

Greg Bila, president of Tissue Regenix Wound Care Inc. said: "Commercialisation of DermaPure continues to progress according to plan. We are working to gain further hospital product evaluation committee approvals as a trigger for future product adoption.

"We are also progressing in the enrolment of patients into human trials in the US."

DermaPure works by taking human donor skin and removing the DNA and cells, using Tissue Regenix’s patented dCELL process to leave a natural biological scaffold that can be placed in the wound to aid natural healing by attracting the patient’s own cells to the wound area.